Engineered Mammalian Cell Lines with Amplified Transgenes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing therapeutic proteins in mammalian cell lines are inefficient due to random genomic integration of genes, leading to clone-to-clone variability and high manufacturing costs, with existing recombinase-based systems being hesitant to adopt new cell lines without FDA approval.
Innovation Solution
Development of mammalian cell lines where exogenous sequences are inserted proximal to endogenous selectable genes in amplifiable loci, allowing co-amplification with the selectable gene and maintaining stability even without selection, using site-specific endonucleases like meganucleases for targeted gene insertion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If random genomic integration of genes is used for producing therapeutic proteins in mammalian cell lines, then gene insertion is simple, but clone-to-clone variability increases and manufacturing precision deteriorates
Solution Approach 1:
The patent applies preliminary action by pre-engineering mammalian cell lines with specific target sites (e.g., ROSA26, H11, or other defined genomic loci) that are optimized for transgene integration. These target sites are prepared in advance with appropriate regulatory elements and chromatin structures to ensure high-level, stable expression. When therapeutic genes are introduced, they integrate into these pre-prepared sites, eliminating the need for extensive screening of random integrants and ensuring consistent expression across cell clones.
Solution Approach 2:
The patent uses intermediary elements such as loxP sites, FRT sites, or other recombinase recognition sequences that are integrated into the genome at target loci. These intermediaries facilitate controlled gene insertion through site-specific recombination. The intermediary sites act as docking platforms that guide the integration of therapeutic genes, ensuring they land in optimal positions for expression while maintaining genomic stability and reducing variability between clones.
2Productivity
If new cell lines are developed for therapeutic protein production, then expression capability can be optimized, but FDA approval complexity and manufacturing time increase
Solution Approach 1:
The patent creates universal target sites (such as ROSA26, H11, or other multi-functional genomic loci) that can accommodate various therapeutic genes while maintaining consistent, high-level expression. These universal sites have been characterized and validated to work with different gene types, promoters, and coding sequences. By using these standardized, pre-characterized target sites across different therapeutic protein productions, manufacturers can leverage existing data and regulatory precedents, reducing the time and complexity of FDA approval for new cell lines.
3Productivity
If extensive screening of cell clones is performed to identify high-expressing clones, then expression level can be maximized, but time and resource consumption increase
Solution Approach 1:
The patent applies local quality by creating specifically optimized genomic loci with enhanced properties for gene expression. These target sites incorporate strong promoters, appropriate enhancers, optimal chromatin accessibility, and favorable nuclear positioning. By concentrating expression-optimizing elements at specific genomic locations, the patent ensures that any gene integrated into these sites will achieve high-level expression without requiring extensive screening. The local genomic environment is engineered to be inherently favorable for transcription and protein production.
4Productivity
If gene amplification is used to increase transgene copy number, then protein production capacity increases, but genomic stability may deteriorate
Solution Approach 1:
The patent applies preliminary action by pre-engineering the target genomic sites with amplification-friendly characteristics. These sites are selected or designed to accommodate controlled gene amplification through mechanisms such as episomal maintenance, integrated amplification, or controlled duplication. The target loci are prepared in advance with appropriate replication origins, segregation control elements, and chromatin structures that support stable amplification. This preliminary preparation allows genes to be amplified to high copy numbers while maintaining genomic integrity and stable inheritance through cell divisions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces heterogeneity and costs by achieving stable, high-level expression of therapeutic proteins with reduced screening needs and compatibility with existing cell lines, enabling efficient biomanufacturing of proteins like monoclonal antibodies.
Implementation Method 1
contacting the cell with a meganuclease, wherein the meganuclease creates a double-stranded break at a recognition sequence in the chromosomal DNA of the cell
Implementation Method 2
The invention relates to methods of inserting genes into defined locations in the chromosomal DNA of cultured mammalian cell lines
Data Source
AI summary
Methods of inserting genes into defined locations in the chromosomal DNA of cultured mammalian cell lines which are subject to gene amplification are disclosed. In particular, sequences of interest (e.g., genes encoding biotherapeutic proteins) are inserted proximal to selectable genes in amplifiable loci, and the transformed cells are subjected to selection to induce co-amplification of the selectable gene and the sequence of interest. The invention also relates to meganucleases, vectors and engineered cell lines necessary for performing the methods, to cell lines resulting from the application of the methods, and use of the cell lines to produce protein products of interest.